Treatment Patterns and Clinical Outcomes in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated in the Community Practice Setting in the United States
Conclusions
Most metastatic gastroenteropancreatic neuroendocrine tumor patients received systemic treatment with SSAs. Patient treatment used an individualized dosing approach. Overall survival and toxicity were consistent with the published literature.
Source: Pancreas - Category: Gastroenterology Tags: Original Articles Source Type: research
More News: Brain | Cancer & Oncology | Chemotherapy | Databases & Libraries | Eating Disorders & Weight Management | Electronic Health Records (EHR) | Gastroenterology | Neurology | Obesity | Pain | Pancreas | Study | Toxicology | USA Health